Studies have confirmed that the combination of imatinib mesylate and PI3K inhibitors in the treatment of GIST xenograft models was more effective, with a more durable response compared to the use of a single-agent [134,137,138]. The gene discussed is PIK3CG; the disease is gastrointestinal stromal tumor.